StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Earnings

Gyre Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$32.90M
+7.5% on a year earlier
EPS, Q3 FY2026
-$0.04
$0.03 a year earlier
Latest guidance
Reaffirmed
Nov 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Gyre Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$32.90M+7.5%-$0.04Release
Q2 FY2026ended Jun 30, 2026Aug 7, 2026before the open$29.10M+8.6%-$0.12Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$22.50M+1.8%-$0.10Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close$37.20M+33.3%-$0.02Release
Q3 FY2025ended Sep 30, 2025Nov 7, 2025after the close$30.60M+20.0%$0.03Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025during market hours$26.80M+6.3%$0.00Release
Q1 FY2025ended Mar 31, 2025May 9, 2025after the close$22.10M-18.8%$0.00Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025during market hours$27.90M–$0.00Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours$25.50M–$0.01Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close$25.20M–$0.01Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$27.20M–$0.03Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Gyre Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$100.50M – $111.00M$100.50M – $111.00MReaffirmedMay 7, 2026
revenue guidanceFY2026$100.50M – $111.00M$100.50M – $111.00MReaffirmedNov 5, 2026

Guidance vs results

The last range Gyre Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$115.00M – $118.00M$116.70MΣ4QWithin range

Guidance history

Every forecast Gyre Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026revenue guidanceFY2026$100.50M – $111.00MReaffirmed
Aug 7, 2026revenueFY2026$100.50M – $111.00MNew
May 7, 2026revenueFY2026$100.50M – $111.00MReaffirmed
Mar 12, 2026revenuesFY2026$100.50M – $111.00MNew
Nov 7, 2025revenue guidanceFY2025$115.00M – $118.00MNew
Aug 11, 2025growth over 2024 revenueFY2025+11.3% – +20.8%Lowered
Aug 11, 2025revenuesFY2025$118.00M – $128.00MReaffirmed
May 9, 2025revenue guidanceFY2025$118.00M – $128.00MReaffirmed
Mar 17, 2025revenuesFY2025$118.00M – $128.00MNew
Feb 18, 2025Operating profitFY202523,217New
Feb 18, 2025Basic earnings per shareFY2025240.42New
Feb 18, 2025RevenueFY202528,733New
Feb 18, 2025Revenue %FY2025+21.7%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Gyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Results
  6. Update
  7. Results
  8. Results
  9. Update
  10. Update
  11. Update
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?